These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7898066)

  • 21. Release of nitric oxide from glyceryl trinitrate by captopril but not enalaprilat: in vitro and in vivo studies.
    Salvemini D; Pistelli A; Mollace V
    Br J Pharmacol; 1993 Jun; 109(2):430-6. PubMed ID: 8358544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance.
    Holmes AS; Chirkov YY; Willoughby SR; Poropat S; Pereira J; Horowitz JD
    Br J Clin Pharmacol; 2005 Oct; 60(4):355-63. PubMed ID: 16187967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S-Transnitrosylation of albumin in human plasma and blood in vitro and in vivo in the rat.
    Tsikas D; Sandmann J; Luessen P; Savva A; Rossa S; Stichtenoth DO; Frölich JC
    Biochim Biophys Acta; 2001 Apr; 1546(2):422-34. PubMed ID: 11295447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro effects of aprosulate sodium, a novel anticoagulant, on platelet activation: possible mechanism for antiplatelet action.
    Sugidachi A; Breiter N; Ogawa T; Asai F; Koike H
    Thromb Haemost; 1996 Nov; 76(5):786-90. PubMed ID: 8950791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term smoking causes nitroglycerin resistance in platelets by depletion of intraplatelet glutathione.
    Haramaki N; Ikeda H; Takajo Y; Katoh A; Kanaya S; Shintani S; Haramaki R; Murohara T; Imaizumi T
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1852-6. PubMed ID: 11701477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of nitric oxide synthase activity in human platelets by nitroglycerin and authentic nitric oxide.
    Chen LY; Mehta JL
    J Investig Med; 1997 Feb; 45(2):69-74. PubMed ID: 9084577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet effects of a novel antianginal agent, nicorandil.
    Jaraki O; Strauss WE; Francis S; Loscalzo J; Stamler JS
    J Cardiovasc Pharmacol; 1994 Jan; 23(1):24-30. PubMed ID: 7511731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antiplatelet activity of rutaecarpine, an alkaloid isolated from Evodia rutaecarpa, is mediated through inhibition of phospholipase C.
    Sheu JR; Kan YC; Hung WC; Su CH; Lin CH; Lee YM; Yen MH
    Thromb Res; 1998 Oct; 92(2):53-64. PubMed ID: 9792112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet effect of amlodipine: a possible mechanism through a nitric oxide-mediated process.
    Chou TC; Li CY; Yen MH; Ding YA
    Biochem Pharmacol; 1999 Nov; 58(10):1657-63. PubMed ID: 10535758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nitric oxide and platelet energy metabolism.
    Tomasiak M; Stelmach H; Rusak T; Wysocka J
    Acta Biochim Pol; 2004; 51(3):789-803. PubMed ID: 15448739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of vascular tissue to the antiplatelet activity of sodium nitroprusside.
    Booth BP; Fung HL
    J Cardiovasc Pharmacol; 1998 Jul; 32(1):129-33. PubMed ID: 9676732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties.
    Keaney JF; Simon DI; Stamler JS; Jaraki O; Scharfstein J; Vita JA; Loscalzo J
    J Clin Invest; 1993 Apr; 91(4):1582-9. PubMed ID: 8473501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor.
    Simon DI; Stamler JS; Jaraki O; Keaney JF; Osborne JA; Francis SA; Singel DJ; Loscalzo J
    Arterioscler Thromb; 1993 Jun; 13(6):791-9. PubMed ID: 8388713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of action of p-chlorobiphenyl on the inhibition of platelet aggregation.
    Ko FN; Yeh LJ; Liang HC; Kuo SC; Teng CM
    J Pharm Pharmacol; 1996 Apr; 48(4):395-400. PubMed ID: 8794990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors.
    Salvemini D; Radziszewski W; Korbut R; Vane J
    Br J Pharmacol; 1990 Dec; 101(4):991-5. PubMed ID: 1707709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of 17beta-estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis.
    Nakano Y; Oshima T; Matsuura H; Kajiyama G; Kambe M
    Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):961-7. PubMed ID: 9633938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.
    Gordge MP; Hothersall JS; Noronha-Dutra AA
    Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
    Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
    Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation.
    Mellion BT; Ignarro LJ; Myers CB; Ohlstein EH; Ballot BA; Hyman AL; Kadowitz PJ
    Mol Pharmacol; 1983 May; 23(3):653-64. PubMed ID: 6135148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of authentic nitric oxide on basal cytosolic [Ca2+] and Ca2+ release from internal stores in human platelets.
    Le Quan Sang KH; Lantoine F; Devynck MA
    Br J Pharmacol; 1996 Dec; 119(7):1361-6. PubMed ID: 8968544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.